10/31/14 CBPO 60.25 China Biologic Products $CBPO
Post# of 46
Posted On: 11/01/2014 11:18:38 PM
10/31/14 CBPO 60.25 China Biologic Products $CBPO Hit a 52 week high of 62.20 Closing the day 10/31/14 at 60.25 +0.60 +1.01% With a day low of 59.89 and a total volume of 81,600.
CBPO Recent Posts: http://investorshangout.com/China-Biologic-Pr...BPO-53617/
CBPO China Biologic Products Recent Headline News
China Biologic to Report Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release third quarter 2014 financial results on Wednesday, November 5, 2014 after the market closes.
CBPO: 60.25 (+0.60)
4 Stocks Spiking on Big Volume
at The Street - Thu Oct 23, 8:30AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
NFLX: 392.77 (+13.76), CBPO: 60.25 (+0.60), LMT: 190.57 (+1.28), TLLP: 56.30 (-0.34)
China Biologic to begin commercial manufacturing of human prothrombin complex concentrate at Shandong Taibang Facility
M2 - Mon Oct 20, 6:48AM CDT
Biopharmaceutical company China Biologic Products (NASDAQ:CBPO) disclosed on Friday the receipt of approval from the China Food and Drug Administration (the CFDA) for commercial manufacturing of human prothrombin complex concentrate (PCC) at its Shandong Taibang facility.
CBPO: 60.25 (+0.60)
China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility
PR Newswire - Fri Oct 17, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has received approval from the China Food and Drug Administration (the "CFDA" for commercial manufacturing of human prothrombin complex concentrate ("PCC" at its Shandong Taibang facility. The CFDA inspected Shandong Taibang's new coagulation factor production facility for Good Manufacturing Practices ("GMP" compliance in June 2013 and is expected to issue the GMP certificate before early December. The Company expects to commence commercial production of PCC at its Shandong Taibang facility immediately upon the receipt of the GMP certificate.
CBPO: 60.25 (+0.60)
Acceleron Pharma (XLRN) Jumps: Stock Rises 12.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 8:39AM CDT
Acceleron Pharma (XLRN) was a big mover last session, as its shares rose almost 13% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), XLRN: 36.98 (-1.26)
Sangamo Biosciences (SGMO) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 7:51AM CDT
Sangamo Biosciences Inc. (SGMO) was a big mover last session, as its shares rose over 5% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), SGMO: 12.14 (+0.23)
Global Eczema Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Wed Sep 24, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5txcp4/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Eczema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eczema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Merck & Co., Inc. - FAES Farma SA - China Biologic Products, Inc. - GlycaNova Norway AS - Immune Response BioPharma, Inc. Drug Profiles - bilastine - desloratadine - Drug for Atopic Dermatitis and Eczema - Varicella Hyperimmune Globulins - IR-444 - MM-1501 For more information visit http://www.researchandmarkets.com/research/5t...a_pipeline
CBPO: 60.25 (+0.60), MRK: 57.94 (+0.63)
OncoMed Pharmaceuticals (OMED) Jumps: Stock Up 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 7:51AM CDT
OncoMed Pharmaceuticals, Inc. (OMED) was a big mover last session, as its shares rose over 5% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), OMED: 20.77 (-1.38)
Integra to Buy Medtronic's MicroFrance, Xomed; Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:10PM CDT
Following this news, Integra's (IART) share price jumped 1.6% to eventually close at $49.76 on Friday.
CBPO: 60.25 (+0.60), IART: 51.11 (+1.37), CBM: 21.08 (+0.22), MDT: 68.16 (+0.73)
Cytori Therapeutics (CYTX) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:39AM CDT
Cytori Therapeutics, Inc. (CYTX) was a big mover last session, as its shares rose over 6% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), CYTX: 0.52 (-0.02)
Vertex Pharmaceuticals (VRTX) Jumps: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 7:51AM CDT
Vertex Pharmaceuticals Incorporated (VRTX) was a big mover last session, as its shares rose almost 7% on the day.
CBPO: 60.25 (+0.60), VRTX: 112.64 (+1.79), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22)
Halozyme's PEGPH20 Study S1313 Clinical Hold Lifted by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:20PM CDT
The FDA has lifted the clinical hold from a phase II study on Halozyme's (HALO) PEGPH20 in combination with modified FOLFIRINOX for advanced pancreatic cancer, which is being conducted by SWOG.
CBPO: 60.25 (+0.60), HALO: 9.62 (+0.01), CBM: 21.08 (+0.22), BAX: 70.14 (+0.08)
VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), VVUS: 3.39 (+0.03)
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:11AM CDT
Arena Pharmaceuticals, Inc. (ARNA) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.
CBPO: 60.25 (+0.60), BIIB: 321.08 (+0.08), CBM: 21.08 (+0.22), ARNA: 4.36 (-0.09)
ImmunoCellular Therapeutics (IMUC) Jumps: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:58AM CDT
ImmunoCellular Therapeutics, Ltd. (IMUC) was a big mover last session, as its shares rose nearly 9% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), IMUC: 0.70 (unch)
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:39AM CDT
Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose over 9% on the day.
CBPO: 60.25 (+0.60), HALO: 9.62 (+0.01), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22)
Regeneron Gets Breakthrough Therapy Status for Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:30PM CDT
Regeneron Pharmaceuticals' (REGN) shares were up 2.7% on the news that the FDA has granted Breakthrough Therapy designation to its eye drug Eylea, for the treatment of diabetic retinopathy in patients suffering from diabetic macular edema.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), REGN: 393.72 (+0.92)
Should You Get Rid of Vital Therapies (VTL) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 7:53AM CDT
Vital Therapies is a stock to drop as it has witnessed negative trend in earnings estimate revisions and has seen its price decline significantly.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), VTL: 17.26 (-0.78)
Genomic Health Reveals Positive Oncotype DX Test Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:00PM CDT
Currently, Genomic Health (GHDX) is focused on boosting its Oncotype DX portfolio in the international market
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), GHDX: 36.34 (+0.27)
Xenoport/NIAAA Collaborate on Alcoholism Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:55PM CDT
Xenoport, Inc. (XNPT) entered into a clinical trial collaboration agreement with the National Institute on Alcohol Abuse and Alcoholism, for a study that will evaluate HORIZANT as a potential treatment for alcohol use disorder (AUD).
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), AMGN: 162.18 (+0.60), XNPT: 6.78 (-0.13)
CBPO Recent Posts: http://investorshangout.com/China-Biologic-Pr...BPO-53617/
CBPO China Biologic Products Recent Headline News
China Biologic to Report Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release third quarter 2014 financial results on Wednesday, November 5, 2014 after the market closes. CBPO: 60.25 (+0.60)
4 Stocks Spiking on Big Volume
at The Street - Thu Oct 23, 8:30AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
NFLX: 392.77 (+13.76), CBPO: 60.25 (+0.60), LMT: 190.57 (+1.28), TLLP: 56.30 (-0.34)
China Biologic to begin commercial manufacturing of human prothrombin complex concentrate at Shandong Taibang Facility
M2 - Mon Oct 20, 6:48AM CDT
Biopharmaceutical company China Biologic Products (NASDAQ:CBPO) disclosed on Friday the receipt of approval from the China Food and Drug Administration (the CFDA) for commercial manufacturing of human prothrombin complex concentrate (PCC) at its Shandong Taibang facility.
CBPO: 60.25 (+0.60)
China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility
PR Newswire - Fri Oct 17, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has received approval from the China Food and Drug Administration (the "CFDA" for commercial manufacturing of human prothrombin complex concentrate ("PCC" at its Shandong Taibang facility. The CFDA inspected Shandong Taibang's new coagulation factor production facility for Good Manufacturing Practices ("GMP" compliance in June 2013 and is expected to issue the GMP certificate before early December. The Company expects to commence commercial production of PCC at its Shandong Taibang facility immediately upon the receipt of the GMP certificate. CBPO: 60.25 (+0.60)
Acceleron Pharma (XLRN) Jumps: Stock Rises 12.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 8:39AM CDT
Acceleron Pharma (XLRN) was a big mover last session, as its shares rose almost 13% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), XLRN: 36.98 (-1.26)
Sangamo Biosciences (SGMO) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 7:51AM CDT
Sangamo Biosciences Inc. (SGMO) was a big mover last session, as its shares rose over 5% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), SGMO: 12.14 (+0.23)
Global Eczema Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Wed Sep 24, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5txcp4/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Eczema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eczema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Merck & Co., Inc. - FAES Farma SA - China Biologic Products, Inc. - GlycaNova Norway AS - Immune Response BioPharma, Inc. Drug Profiles - bilastine - desloratadine - Drug for Atopic Dermatitis and Eczema - Varicella Hyperimmune Globulins - IR-444 - MM-1501 For more information visit http://www.researchandmarkets.com/research/5t...a_pipeline
CBPO: 60.25 (+0.60), MRK: 57.94 (+0.63)
OncoMed Pharmaceuticals (OMED) Jumps: Stock Up 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 7:51AM CDT
OncoMed Pharmaceuticals, Inc. (OMED) was a big mover last session, as its shares rose over 5% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), OMED: 20.77 (-1.38)
Integra to Buy Medtronic's MicroFrance, Xomed; Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:10PM CDT
Following this news, Integra's (IART) share price jumped 1.6% to eventually close at $49.76 on Friday.
CBPO: 60.25 (+0.60), IART: 51.11 (+1.37), CBM: 21.08 (+0.22), MDT: 68.16 (+0.73)
Cytori Therapeutics (CYTX) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:39AM CDT
Cytori Therapeutics, Inc. (CYTX) was a big mover last session, as its shares rose over 6% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), CYTX: 0.52 (-0.02)
Vertex Pharmaceuticals (VRTX) Jumps: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 7:51AM CDT
Vertex Pharmaceuticals Incorporated (VRTX) was a big mover last session, as its shares rose almost 7% on the day.
CBPO: 60.25 (+0.60), VRTX: 112.64 (+1.79), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22)
Halozyme's PEGPH20 Study S1313 Clinical Hold Lifted by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:20PM CDT
The FDA has lifted the clinical hold from a phase II study on Halozyme's (HALO) PEGPH20 in combination with modified FOLFIRINOX for advanced pancreatic cancer, which is being conducted by SWOG.
CBPO: 60.25 (+0.60), HALO: 9.62 (+0.01), CBM: 21.08 (+0.22), BAX: 70.14 (+0.08)
VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), VVUS: 3.39 (+0.03)
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:11AM CDT
Arena Pharmaceuticals, Inc. (ARNA) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.
CBPO: 60.25 (+0.60), BIIB: 321.08 (+0.08), CBM: 21.08 (+0.22), ARNA: 4.36 (-0.09)
ImmunoCellular Therapeutics (IMUC) Jumps: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:58AM CDT
ImmunoCellular Therapeutics, Ltd. (IMUC) was a big mover last session, as its shares rose nearly 9% on the day.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), IMUC: 0.70 (unch)
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:39AM CDT
Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose over 9% on the day.
CBPO: 60.25 (+0.60), HALO: 9.62 (+0.01), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22)
Regeneron Gets Breakthrough Therapy Status for Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:30PM CDT
Regeneron Pharmaceuticals' (REGN) shares were up 2.7% on the news that the FDA has granted Breakthrough Therapy designation to its eye drug Eylea, for the treatment of diabetic retinopathy in patients suffering from diabetic macular edema.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), REGN: 393.72 (+0.92)
Should You Get Rid of Vital Therapies (VTL) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 7:53AM CDT
Vital Therapies is a stock to drop as it has witnessed negative trend in earnings estimate revisions and has seen its price decline significantly.
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), VTL: 17.26 (-0.78)
Genomic Health Reveals Positive Oncotype DX Test Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:00PM CDT
Currently, Genomic Health (GHDX) is focused on boosting its Oncotype DX portfolio in the international market
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), GHDX: 36.34 (+0.27)
Xenoport/NIAAA Collaborate on Alcoholism Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:55PM CDT
Xenoport, Inc. (XNPT) entered into a clinical trial collaboration agreement with the National Institute on Alcohol Abuse and Alcoholism, for a study that will evaluate HORIZANT as a potential treatment for alcohol use disorder (AUD).
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), AMGN: 162.18 (+0.60), XNPT: 6.78 (-0.13)
(0)
(0)